Newsroom | 6215 results

LONDON--(BUSINESS WIRE)--AviadoBio Presents New Safety and Biomarker Data from the Phase 1/2 ASPIRE-FTD Trial at the International Conference on Frontotemporal Dementias...

HOUSTON--(BUSINESS WIRE)--The Rice Alliance for Technology and Entrepreneurship and BioHouston today announced that the 15th Annual Texas Life Science Forum is set for Tuesday, Nov. 10, at McNair Hall at Rice University. The Forum will bring together entrepreneurs, investors, industry executives, and academic and clinical leaders from Texas and nationwide to focus discussion on the promising science and technology in the state that serves as the backbone for new businesses and is an overall dri...

AUSTIN, Texas--(BUSINESS WIRE)--Paradromics Inc., a neurotechnology company developing high-data-rate brain-computer interfaces (BCIs) to restore and enhance human capabilities, today announced that its brain-computer interface has demonstrated more than four years of stable neural recording and decoding performance.The four-year milestone comes from two sheep implanted with Paradromics cortical modules representative of the electrode technology used in the Connexus® BCI. Through ongoing follow-...

NEW YORK--(BUSINESS WIRE)--Outro, the first neuroscience-based platform helping Americans safely discontinue psychiatric medications, today announced $7 million funding across pre-seed and seed rounds, with participation from Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group, Pave Health Ventures, and more.Approximately one in six Americans take an antidepressant. The average duration of use has surpassed five years, whi...

HANOVER, N.H.--(BUSINESS WIRE)--Argus Cognitive, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Neurora (510(k) K260064), a tool that gives clinicians objective behavioral measures to support the diagnosis of autism in children ages 18 months through 12 years.Autism now affects 1 in 31 children in the United States, according to the Centers for Disease Control and Prevention (CDC). Yet the median age of diagnosis is nearly 4, and only about half of autistic chi...

BASEL, Switzerland--(BUSINESS WIRE)--aiPTO TechBio today released a preprint [link] describing DELPHAI (Deep Explainable Perturbation Heterogeneity-Aware Inference), its virtual tumor model for perturbation prediction. In two independent benchmarking frameworks (Wei et al., Nature Methods 2026; Radig et al., Genome Biology 2026), DELPHAI achieved the #1 ranking on differentially expressed gene (DEG) recovery, outperforming state-of-the-art virtual cell models. It predicts drug responses for prev...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, and the 15-20 National Hospital (l’Hôpital national des 15-20) in Paris today announced the publication of the results of the GS030 PIONEER trial in the prestigious medical journal The New England Journal of Medicine...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, et l’Hôpital national des 15-20 à Paris, annoncent aujourd’hui la publication des résultats de l’essai PIONEER évaluant GS030 dans la prestigieuse revue médicale The New Englan...

PARIS--(BUSINESS WIRE)--Regulatory News: NE PAS DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE, AU CANADA, EN AUSTRALIE, AU JAPON ET EN AFRIQUE DU SUD GenSight Biologics (la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et les troubles du système nerveux central, a annoncé aujourd...

PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics ("GenSight" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion of a EUR 1,000,000.208 f...